Drug Combination Details
| General Information of the Combination (ID: C50887) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | Gefitinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H1975 | CVCL_1511 | Lung adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Combined treatment with triptolide and tyrosine kinase inhibitors synergistically enhances apoptosis in non-small cell lung cancer H1975 cells but not H1299 cells through EGFR/Akt pathway. | |||||
| β. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | SNAI1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | The A549/siE-cad cells (2*106) were injected subcutaneously into the underarms of the right forelimbs of 6-week-old BCLB/c mice. | |||||
| Experimental
Result(s) |
Triptolide inhibits epithelial mesenchymal transition and induces apoptosis in gefitinib resistant lung cancer cells. | |||||
